



MEMORANDUM

TO: Valued CHIP, STAR & STAR+PLUS Providers

FROM: El Paso Health

DATE: 10/09/2024

RE: Change in Preferred Drug List Status for Generic Sildenafil Oral Suspension Takes Effect Sept. 25

The drug manufacturer discontinued the brand name Revatio oral suspension products on Aug. 16, 2024. In response, the Texas Health and Human Services Commission removed the non-preferred status from the generic sildenafil oral suspension products on the preferred drug list (PDL). The preferred status of brand Revatio oral suspension products will not change, allowing pharmacies to use the existing stock of these medications.

HHSC removed the non-preferred status for the following drugs in the table below, effective Sept. 25, 2024. These changes allow providers to prescribe the authorized generic sildenafil oral suspension products without requiring a PDL prior authorization and continue access to necessary medication for members.

NDC	Drug Name
00591405094	SILDENAFIL 10MG/ML ORAL SUSP
27241017529	SILDENAFIL 10MG/ML ORAL SUSP
31722013631	SILDENAFIL 10MG/ML ORAL SUSP
59762205801	SILDENAFIL 10MG/ML ORAL SUSP
68180028301	SILDENAFIL 10MG/ML ORAL SUSP
69238157401	SILDENAFIL 10MG/ML ORAL SUSP
70710171604	SILDENAFIL 10MG/ML ORAL SUSP
70954016810	SILDENAFIL 10MG/ML ORAL SUSP
72205005976	SILDENAFIL 10MG/ML ORAL SUSP

Administration for procedure code 90683 may be reimbursed when billed with corresponding vaccine administration procedure code 90471 or 90472.

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com.